Immix Biopharma, Inc. announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a digital filter that filters out non-specific activation. The Company plans to release forthcoming clinical data at upcoming scientific forums.